Filters
Catalog peptides
Synthesis of unnatural amino acids and other blocks

Ovalbumin(257-264) antigen peptide

Name
Ovalbumin(257-264) antigen peptide
Molecular structural formula
Purity
≥95%
CAS Number
138831-86-4
Formula
C74H120N26O25
MW
1773.9
Target
others
Sequence
Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg
Sequence Shortening
SIINFEKL
InChIKey
JVJGCCBAOOWGEO-RUTPOYCXSA-N
References
[1]. Wick MJ, Pfeifer JD. Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Eur J Immunol. 1996 Nov;26(11):2790-9. [2]. Doherty PC, Christensen JP. Accessing complexity: the dynamics of virus-specific T cell responses. Annu Rev Immunol. 2000;18:561-92. doi: 10.1146/annurev.immunol.18.1.561. PMID: 10837069. [3]. Grolleau-Julius A, Harning EK,et,al. Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res. 2008 Aug 1;68(15):6341-9. doi: 10.1158/0008-5472.CAN-07-5769. PMID: 18676859; PMCID: PMC2575813. [4]. Fujinami N, Yoshikawa T, et,al. Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model. Biochem Biophys Rep. 2016 Feb 19;5:482-491. doi: 10.1016/j.bbrep.2016.02.010. PMID: 28955856; PMCID: PMC5600353. [5]. Dong X, Li B, et,al. Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice. PLoS One. 2021 Jan 7;16(1):e0245207. doi: 10.1371/journal.pone.0245207. PMID: 33411807; PMCID: PMC7790389.
* All products on our website are for scientific research and cannot be used in human body
Product details
Data download

OVA Peptide (257-264) is an MHC Class I (Kb) -restricted OVA polypeptide epitope, an octapeptide derived from ovalbumin presented by Class I MHC molecule H-2Kb.It can be used to stimulate T cell activation and activate the immune response of CD8+ cytotoxic T lymphocytes (CTL).OVA peptide (257-264) (injected intradermally at the base of the tail) combined with anti-CD4-monoclonal antibody increased the number of peptide-specific CTLs and showed a higher therapeutic effect against OVA-expressing tumors in mice. Spleen cells pulsed with OVA peptide (257-264)( 250 μg-1mg) are sensitive to Poria cocos polysaccharide (PCP). OVA peptide (257-264) can be used as a self-assembled nanovaccine (I-OVA NE), which enhances peptid-specific CD8+T cells and exhibits ova257-264 specific CTL activity and Th1 immune response. Mice anterior chamber inoculation of OVA Peptide (257-264) (250 μg) could induceanterior chamber associated immune deviation (ACAID) as evidenced by an impaired delayed-type hypersensitivity (DTH) response  .